Gene: PARP2

10038
ADPRT2|ADPRTL2|ADPRTL3|ARTD2|PARP-2|pADPRT-2
poly(ADP-ribose) polymerase 2
protein-coding
14q11.2
Ensembl:ENSG00000129484 MIM:607725 Vega:OTTHUMG00000166106 UniprotKB:Q9UGN5
NG_033959.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND|AD
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
7.373e-1 (AD)  9.543e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs3093927chr14:20354936 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
TOMM200.94
NIF3L10.938
ERCC30.938
DNM1L0.937
MKRN10.936
AGK0.935
SLU70.934
DDX240.934
ASH2L0.931
REEP50.93

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.592
OR4F29-0.571
MTRNR2L9-0.37
MTRNR2L6-0.367
MTRNR2L10-0.347
WDR38-0.347
EVC2-0.34
NKX6-1-0.339
HEY2-0.329
TTLL10-0.319

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB07232VeliparibSmall Molecule912444-00-9InvestigationalTarget
DB09074OlaparibSmall Molecule763113-22-0ApprovedTarget
DB11793NiraparibSmall Molecule1038915-60-4Approved|InvestigationalTarget
DB12332RucaparibSmall Molecule283173-50-2Approved|InvestigationalTarget
ID Drug Name Action PubMed
C0294972,3-bis(3'-hydroxybenzyl)butyrolactone"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARP2 mRNA"19167446
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of PARP2 mRNA"21346803
C1087293,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone"3,4-dihydro-5-(4-(1-piperidinyl)butoxy)-1(2H)-isoquinolinone results in decreased activity of PARP2 protein"21417348
C0251603-aminobenzamidePARP2 protein binds to 3-aminobenzamide20092359
C0179063-dinitrobenzene3-dinitrobenzene results in decreased expression of PARP2 mRNA21983209
C4114255-aminoisoquinolinone5-aminoisoquinolinone results in decreased activity of PARP2 protein21417348
D000082AcetaminophenAcetaminophen results in increased expression of PARP2 mRNA22230336
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of PARP2 mRNA24449571
C006632arsenic trioxidearsenic trioxide results in increased expression of PARP2 mRNA20458559
D001280AtrazineAtrazine results in increased expression of PARP2 mRNA25929836
C547126AZM551248AZM551248 results in decreased expression of PARP2 mRNA22323515
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of PARP2 mRNA22228805
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of PARP2 mRNA"20382639
C044887beta-methylcholinebeta-methylcholine affects the expression of PARP2 mRNA21179406
C006780bisphenol Abisphenol A results in decreased expression of PARP2 mRNA29275510
C006780bisphenol Abisphenol A results in increased expression of PARP2 mRNA25181051
D002994ClofibrateClofibrate results in decreased expression of PARP2 mRNA12851107
D003375Coumestrol"[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARP2 mRNA"19167446
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in increased expression of PARP2 mRNA19167446
D003375CoumestrolCoumestrol results in increased expression of PARP2 mRNA19167446
C408982CPG-oligonucleotideCPG-oligonucleotide results in decreased expression of PARP2 mRNA21878529
D016572CyclosporineCyclosporine results in increased expression of PARP2 mRNA25562108
C017160cypermethrincypermethrin results in increased expression of PARP2 mRNA27704156
D003703DemecolcineDemecolcine results in decreased expression of PARP2 mRNA23649840
D002945CisplatinCisplatin results in increased expression of PARP2 mRNA27594783
D002945CisplatinCisplatin results in increased expression of PARP2 protein21274007
D002117CalcitriolCalcitriol results in decreased expression of PARP2 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in decreased expression of PARP2 mRNA21592394
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of PARP2 mRNA17942748
D004997Ethinyl Estradiol[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PARP2 mRNA17942748
C039281furanfuran results in decreased expression of PARP2 mRNA22507866
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PARP2 mRNA25613284
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of PARP2 mRNA24796395
C410337K 7174K 7174 results in decreased expression of PARP2 mRNA24086573
D007854LeadLead results in decreased expression of PARP2 mRNA19921347
C045463leflunomideleflunomide results in decreased expression of PARP2 mRNA28988120
C052901lemongrass oillemongrass oil results in decreased expression of PARP2 mRNA25660481
D008727MethotrexateMethotrexate results in increased expression of PARP2 mRNA24449571
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in increased expression of PARP2 mRNA23649840
D008770MethylnitrosoureaPARP2 gene mutant form results in increased susceptibility to Methylnitrosourea12727891
C434926N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride"N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in decreased activity of PARP2 protein"21417348
C531550olaparibolaparib results in decreased activity of PARP2 protein21417348
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in decreased expression of PARP2 mRNA25729387
C059514resveratrol[Coumestrol co-treated with resveratrol] results in increased expression of PARP2 mRNA19167446
D012999SomanSoman results in decreased expression of PARP2 mRNA19281266
D013739Testosterone[Testosterone co-treated with Calcitriol] results in decreased expression of PARP2 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of PARP2 mRNA21592394
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PARP2 mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PARP2 mRNA21570461
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of PARP2 mRNA17942748
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of PARP2 mRNA17942748
D013755Tetradecanoylphorbol AcetateTetradecanoylphorbol Acetate results in increased expression of PARP2 mRNA19031421
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of PARP2 mRNA25613284
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in decreased expression of PARP2 mRNA25729387
D019772TopotecanTopotecan results in decreased expression of PARP2 mRNA25729387
D014635Valproic AcidValproic Acid affects the expression of PARP2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of PARP2 mRNA23179753
D014635Valproic AcidValproic Acid results in decreased methylation of PARP2 gene29154799
C521013veliparibPARP2 protein binds to veliparib20092359
C521013veliparibveliparib results in decreased activity of PARP2 protein19143569|2191775
C521013veliparibveliparib results in decreased activity of PARP2 protein17473206|2141734
D014750VincristineVincristine results in decreased expression of PARP2 mRNA23649840

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003677DNA binding-IEA-  
GO:0003950NAD+ ADP-ribosyltransferase activity-IBA21873635  
GO:0003950NAD+ ADP-ribosyltransferase activity-IEA-  
GO:0005515protein binding-IPI21812934  27067600  28190768  
GO:1990404protein ADP-ribosylase activity-IDA28190768  
GO ID GO Term Qualifier Evidence PubMed
GO:0006281DNA repair-TAS7260241  
GO:0006284base-excision repair-IEA-  
GO:0006471protein ADP-ribosylation-TAS7260241  
GO:0018312peptidyl-serine ADP-ribosylation-IDA28190768  
GO:0061051positive regulation of cell growth involved in cardiac muscle cell development-IEA-  
GO:0097191extrinsic apoptotic signaling pathway-IEA-  
GO:1901215negative regulation of neuron death-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA-  
GO:0005654nucleoplasm-IDA15615785  
GO:0005730nucleolus-IDA15615785  
KEGG ID KEGG Term
hsa03410Base excision repair
Reactome ID Reactome Term Evidence
R-HSA-110362POLB-Dependent Long Patch Base Excision RepairTAS
R-HSA-110373Resolution of AP sites via the multiple-nucleotide patch replacement pathwayTAS
R-HSA-5685939HDR through MMEJ (alt-NHEJ)TAS
R-HSA-5693532DNA Double-Strand Break RepairTAS
R-HSA-5693538Homology Directed RepairTAS
R-HSA-5696394DNA Damage Recognition in GG-NERTAS
R-HSA-5696395Formation of Incision Complex in GG-NERTAS
R-HSA-5696398Nucleotide Excision RepairTAS
R-HSA-5696399Global Genome Nucleotide Excision Repair (GG-NER)TAS
R-HSA-5696400Dual Incision in GG-NERTAS
R-HSA-73884Base Excision RepairTAS
R-HSA-73894DNA RepairTAS
R-HSA-73933Resolution of Abasic Sites (AP sites)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
26033827Genetic variation affects congenital heart defect susceptibility in offspring exposed to maternal tobacco use. (2015 Oct)Tang XBirth Defects Res A Clin Mol Teratol